KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Equity Average (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Equity Average for 7 consecutive years, with $9.7 billion as the latest value for Q4 2025.

  • Quarterly Equity Average fell 6.14% to $9.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.7 billion through Dec 2025, down 6.14% year-over-year, with the annual reading at $10.0 billion for FY2025, 1.81% down from the prior year.
  • Equity Average hit $9.7 billion in Q4 2025 for Royalty Pharma, up from $9.6 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $10.4 billion in Q3 2022 to a low of $9.6 billion in Q3 2025.
  • Historically, Equity Average has averaged $10.0 billion across 5 years, with a median of $10.0 billion in 2022.
  • Biggest five-year swings in Equity Average: skyrocketed 48.32% in 2021 and later dropped 6.85% in 2023.
  • Year by year, Equity Average stood at $10.3 billion in 2021, then decreased by 3.36% to $10.0 billion in 2022, then fell by 1.37% to $9.8 billion in 2023, then increased by 4.74% to $10.3 billion in 2024, then decreased by 6.14% to $9.7 billion in 2025.
  • Business Quant data shows Equity Average for RPRX at $9.7 billion in Q4 2025, $9.6 billion in Q3 2025, and $9.6 billion in Q2 2025.